sparkling, thickening of mitral leaflets and mild LV systolic dysfunction (Figs 2A, B) . Based on these findings the patient was diagnosed with diastolic heart failure as a complication of CA. Because CA was advanced and could not be treated by the existing standard treatment regimen, the patient was started on thalidomide (200 mg/day) and dexamethasone (stopped after initial 6 months) as a proposed new treatment option. Treatment-related toxicity, such as anorexia, constipation and depression, occurred initially, but gradually subsided. After treatment, the degree of dyspnea improved from New York Heart Association class grade IV to grade II, the ecchymoses disappeared and the edema in the lower limbs decreased. There were positive changes in the electrocardiographics findings, such as improvement of low voltage and disappearance of the poor R progression, at 3-month follow-up. Light-chain amyloid was not found on protein electrophoresis after the 3 rd month of treatment, and the proteinuria disappeared after 5 months of treatment. On the follow-up TTE, the granular sparkling had begun to decrease significantly and the cardiac function showed improvement. In particular, the diastolic function showed remarkable improvement, from an irreversible restrictive pattern (Grade IV) to a pseudonormal pattern (Grade II) (Figs 2C-F, Table 1 ), consistent with improvement of heart failure symptoms, although there was no significant decrease in the thickness of the cardiac wall or in the level of BNP (Table 1) . On the latest follow-up (15 months) at the outpatient clinic, the patient is stable, and laboratory and echocardiographic findings show sustained complete response.
Discussion
Several methods of treating AL amyloidosis with chemotherapy or organ transplantation have had variable results. High-dose melphalan with autologous stem-cell transplantation has been the mainstay of treatment and complete remission is possible in some patients. However, these treatments are limited for cases of CA with heart failure because of the treatment-related mortality, and in cases of AL amyloidosis invading the heart, there is no effective treatment. 2,4-6 Therefore, advanced CA has been considered as untreatable and affected patients receive conservative treatment. CA is the leading cause of death in patients with and 11 months (Panels E, F) shows a significant decrease in the granular sparkling, and improvement of the the E/A ratio and deceleration time of the early mitral inflow compared with the initial evaluation. However, the thickness of left ventricular wall has not decreased. E, early diastolic filling velocity; A, filling velocity after atrial contration.
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systemic amyloidosis, and the overall prognosis still remains poor, although there are new emerging therapies, including thalidomide, bortezomib, and lenalidomide. 7 Patients treated with thalidomide have been reported to have improvement of symptoms and organ function, but without improvement of CA. 4 Interestingly, in the present case, which we treated with thalidomide, we noted a striking improvement of echocardiographic findings and a rapid, sustained complete response of the laboratory parameters, as well as an extension of survival time. These findings suggest that thalidomide could be used as an alternative treatment regimen for cases of CA and heart failure. The possible matrix stabilizing effect and anti-inflammatory effect of thalidomide, which improve the granular sparkling and decrease heart mass, might improve diastolic heart function. 9 Previous reports proposed that increased BNP levels, LV wall thickness greater than 15 mm and impaired systolic function are poor prognostic factors. 7, 8 In particular, BNP level has been reported to be more sensitive than conventional echocardiographic parameters in detecting clinical improvement or worsening of CA during follow-up. 8 However, in the present case, neither the BNP level nor the thickened LV wall showed significant changes and did not reflect the response to treatment at follow-up. Instead, improvement of diastolic function was accompanied by improvement of symptoms.
It is well known that the BNP level increases when the LV is stressed, and it acts as a protective agent, preventing hypertrophy and fibrosis of cardiomyocytes. Nils et al have reported that the level of BNP is more related to the preoperative LV mass, rather than being a symptom, and elevated levels are maintained up to 12 months following surgery for aortic stenosis, 9 which is similar to the present case and suggest that either there may not be a correlation between BNP and symptoms 10 or a longer follow up period is needed to observe a decrease in the BNP level. 10 Therefore, this case illustrates the usefulness of close echocardiographic monitoring of diastolic function for evaluating the treatment response of CA.
